NovoCure Ltd — Director's Dealing 2021

Mar 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2021-02-27

Reporting Person: Danziger Asaf (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-27	Ordinary Shares	M	9259	$149.10	Acquired	206944	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-27	Restricted Stock Units	$0.0	M	9259	Disposed		Ordinary Shares (9259.0)	Direct

Footnotes

F1: Fully vested as of the date hereof.